Loading…
← CockpitCompetitor Analysis › ANTHEM.NS Anthem BiosciencesOpen in the cockpit ↗

Anthem BiosciencesANTHEM.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Biotechnology

Indian contract research, development and manufacturing (CRDMO) company providing drug discovery, development and manufacturing services to global pharma/biotech clients.

≈ India's smaller Lonza/CatalentMomentum strong 75
Mkt cap
$5.51B
US dollars, full cap
Free float
19%
of shares outstanding
$/day
$4.07M
20-day average traded
Fwd P/E
64.3×
forward earnings
ROIC−WACC
+9.6 pp
WACC 10.8%
Hurdle
+11 pp
Req g minus delivered
Next earnings
105 days
3 Mar 2027
Close · INR₹914.35
1D-1.1%
1W-4.5%
1M+13.1%
3M+2.6%
6M+16.1%
YTD+40.4%
1Y+33.2%
ATR %2.9%
Beta0.53
52w lowhigh7.6% off high

What Anthem Biosciences does

Indian contract research, development and manufacturing (CRDMO) company providing drug discovery, development and manufacturing services to global pharma/biotech clients.

In one line: India's smaller Lonza/Catalent.

Products and services

  • Contract research (drug discovery)
  • Contract development & manufacturing (CDMO)
  • Specialty fermentation-based APIs

Customers

  • Global pharmaceutical and biotech companies

Where it sits in the supply chain

  • Healthcare
  • Pharma services
  • CRDMO - India

What could go right

  • China+1 shift of global pharma outsourcing to India
  • CDMO capacity expansion

What could go wrong

  • Customer/project concentration risk
  • Global biotech R&D funding cyclicality

Moat: narrow (process know-how, customer qualification, regulatory licence). Regulatory-approved manufacturing facilities and scientific expertise create switching costs for pharma clients.

Headquarters: Bengaluru, India · Founded: 2006 · Employees: 3,302

Named competitors

Anthem Biosciences at a glance

Size Anthem Biosciences (ANTHEM.NS) is an India Health Care company (Biotechnology) with a market value of $5.51B, the 200th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹914.35 on 18 Nov 2026.

Performance Over six months the shares gained 16.1%, against -3.5% for the median peer and +3.8% for the India market (cap-weighted) — 8th highest of 21 in its peer set.

Growth Revenue fell 1.2% over the last twelve months (peer median +2.4%); the operating margin is 34.8% (peer median -18.9%).

Valuation It trades at 64.3× forward earnings against a peer median of 53.7× (4th cheapest of 7).

Price implies For today's price to make sense, revenue must grow about 37% a year for seven years (Req g). Recent delivered growth is +26%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 9.6 points above its cost of capital (10.8% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010011012021 May 202621 Aug 202618 Nov 2026ANTHEM.NS 117Peer median 98
Six months, rebased to 100: Anthem Biosciences against the median of its 20 peers (local-currency closes).

Anthem Biosciences financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹20.5B₹21.2B₹18.4B₹14.2B₹10.6B
Revenue growth—+15%+30%+34%—
Gross profit₹9.20B₹7.97B₹6.70B₹5.06B₹4.49B
EBITDA₹8.46B₹8.61B₹6.83B₹5.15B₹4.35B
Net income₹6.14B₹5.92B₹4.51B₹3.67B₹3.85B
Free cash flown/a₹7.06B₹644M-₹1.18B₹1.54B
Capital expendituren/a₹2.11B₹2.61B₹2.97B₹1.95B
Total debt₹412M₹539M₹1.13B₹2.39B₹1.26B

Quarterly statements and history in the cockpit →

Anthem Biosciences competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%+100%+150%-20%0%+20%CAI300122SRRKARWR300347COGTKODDNTHADPT002252EWTX000661IMVTAXSM1530CGON603392TXG6696CRSPANTHEM.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Anthem Biosciences is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%25×50×75×100×CAI300347002252000661AXSM1530ANTHEM.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Anthem Biosciences is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%25%50%CAI300122300347000661TXGANTHEM.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Anthem Biosciences is the large dot.

Anthem Biosciences competitors and peer comparison

Head to head with its named competitors (ANTHEM.NS vs SYNGENE.NS vs DIVISLAB.NS vs LAURUSLABS.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Anthem Biosciences ANTHEM.NS$5.51B+16%-1%35%64.3×36.9%
Syngene International SYNGENE.NS$1.88B-8%-6%13%70.7×36.4%
Divi's Laboratories DIVISLAB.NS$31.3B+60%+22%34%73.5×47.1%
Laurus Labs LAURUSLABS.NS$13.4B+73%+23%24%76.4×51.2%

How Anthem Biosciences compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Anthem Biosciences against its 20 peers (data as of 18 Nov 2026)
MeasureANTHEM.NSPeer medianRank in peer set
1-month return+13.1%-3.4%6th highest of 21
6-month return+16.1%-3.5%8th highest of 21
Distance from 52-week high-7.6%-32.6%highest of 21
Revenue growth (TTM)-1.2%+2.4%8th highest of 15
Operating margin34.8%-18.9%2nd highest of 16
Forward P/E64.3×53.7×4th cheapest of 7
Growth the price implies (Req g, 7 yrs)36.9%25.9%2nd most demanding of 6
Growth delivered (Del g)+26.2%+16.4%2nd highest of 6
Hurdle (Req g minus delivered)+10.7 pp+9.4 pp3rd most demanding of 6
ROIC minus cost of capital+9.6 pp-11.2 pp3rd highest of 12
EV / EBITDA60.1×n/a—
Net debt / EBITDA-0.8×n/a—

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Anthem Biosciences ANTHEM.NSIndia$5.51B+16%-1%35%64.3×36.9%+26.2%
Caris Life Sciences CAIUnited States$5.59B+24%+61%13%79.4×18.2%+61.5%
Chongqing Zhifei Biological Products 300122.SZChina$5.28B-1%-28%-210%n/a-6.5%-10.0%
Scholar Rock SRRKUnited States$5.86B-1%n/a-71,732%n/an/an/a
Arrowhead Pharmaceuticals ARWRUnited States$6.09B-44%-46%-157%n/an/an/a
Hangzhou Tigermed Consulting 300347.SZChina$4.88B-2%+16%10%97.0×25.9%+16.4%
Cogent Biosciences COGTUnited States$4.84B-16%n/an/an/an/an/a
Kodiak Sciences KODUnited States$6.40B+170%n/an/an/an/an/a
Dianthus Therapeutics DNTHUnited States$4.73B-5%-12%-8,684%n/an/an/a
Adaptive Biotechnologies ADPTUnited States$4.61B+104%+18%-16%n/an/an/a
Shanghai RAAS Blood Products 002252.SZChina$4.57B-15%-22%17%12.8×n/an/a
Edgewise Therapeutics EWTXUnited States$4.53B+26%n/an/an/an/an/a
Changchun High-Tech Industry (Group) 000661.SZChina$4.52B-13%-18%-1%30.3×32.4%+7.1%
Immunovant IMVTUnited States$6.86B-7%n/an/an/an/an/a
Axsome Therapeutics AXSMUnited States$7.05B-42%+54%-19%77.1×n/an/a
3SBio 1530.HKHong Kong$4.28B-31%+102%61%12.0×n/an/a
CG Oncology CGONUnited States$7.15B+24%+184%-4,294%n/an/an/a
Beijing Wantai Biological Pharmacy Enterprise 603392.SSChina$4.20B-43%+8%-35%n/an/an/a
10x Genomics TXGUnited States$7.51B+138%-4%-11%n/a47.2%+16.6%
Lin BioScience 6696.TWOTaiwan$3.98B+305%n/an/an/an/an/a
CRISPR Therapeutics CRSPUnited States$3.90B-17%-34%-2,059%n/an/an/a

Questions

Who are Anthem Biosciences's main competitors?
Named competitors: Syngene International (SYNGENE.NS), Divi's Laboratories (DIVISLAB.NS), Laurus Labs (LAURUSLABS.NS). The cockpit's measured peer set (industry) also includes Caris Life Sciences (CAI), Chongqing Zhifei Biological Products (300122.SZ), Scholar Rock (SRRK), Arrowhead Pharmaceuticals (ARWR), Hangzhou Tigermed Consulting (300347.SZ), Cogent Biosciences (COGT).
Is Anthem Biosciences expensive compared with its peers?
On forward p/e it trades at 64.3× against a peer median of 53.7×, 4th cheapest of 7 in its peer set. For today's price to make sense, revenue must grow about 37% a year for seven years (Req g). Recent delivered growth is +26%, so the hurdle is +11 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Anthem Biosciences stock performed?
Over six months to 18 Nov 2026 the shares returned +16.1% against -3.5% for the median peer; over one year +33.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.